Table 1. Expression of genes involved in apoptosis in LS-174T i.p. xenografts following treatment with Paclitaxel and ²¹²Pb-trastuzumab.

Symbol	Gene name	GeneBank ID	Fold change
			Paclitaxel-212Pb-trastuzumab	p	Paclitaxel-212Pb-HuIgG	p	Paclitaxel	p
BRCA1	Breast Cancer 1, early onset	NM_007294	-3.8	0.0005	−3.0	0.0022	−2.1	0.0061
CIDEA	Cell death-inducing DEFA-like effector a	NM_001279	14.0	0.0067	3.8	0.0654	1.1	0.4741
GADD45α	Growth arrest and DNA-damage-inducible, alpha	NM_001924	5.9	0.0001	3.8	0.0002	1.9	0.0962
GADD45γ	Growth arrest and DNA-damage-inducible, gamma	NM_006705	10.9	0.0001	9.4	0.0002	2.4	0.0067
GML	Glycosylphosphatidylinositol anchored molecule like protein	NM_002066	26.4	0.0004	2.7	0.0023	−1.4	0.4430
IP6K3	Inositol hexakisphosphate kinase 3	NM_054111	18.1	0.0001	8.7	0.0843	−1.1	0.6288
PCBP4	Poly(rC)binding protein 2	NM_020418	3.1	0.0116	2.8	0.0012	1.6	0.0205
PPP1R15A	Protein phosphatase 1, regulatory subunit 15A	NM_014330	2.6	0.0115	1.4	0.0399	−1.1	0.4490
RAD21	RAd21 homolog	NM_006265	−3.1	0.0001	−2.5	0.0002	−1.7	0.0184
p73	Tumor protein p73	NM_005427	2.6	0.0009	5.6	0.0021	2.9	0.0628

Mice bearing i.p. LS-174T xenografts were treated by Pac/²¹²Pb-trastuzumab for 24 h. qRT-PCR array was used for gene expression analysis in three independent experiments. The numbers indicate fold change compared to untreated control (2-fold change cut-off). Additional groups included paclitaxel alone and Pac/²¹²Pb-HuIgG as a nonspecific control antibody. Results represent the average of a minimum of three replicates. A p-value <0.05 was considered significantly significant.